Please note that following on from information provided to NICE by the company in May 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
 
Status Discontinued
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 5112

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 November 2024 Discontinued. Please note that following on from information provided to NICE by the company in May 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
26 May 2023 Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
30 March 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer have been revised. It is anticipated that the appraisal will begin in early-October 2023 when we will write to you about how you can get involved.
14 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual